Sight Sciences, Inc. SGHT
We take great care to ensure that the data presented and summarized in this overview for Sight Sciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SGHT
View all-
Kck Ltd. Tortola, D84.65MShares$30.5 Million22.26% of portfolio
-
Bank Of America Corp Charlotte, NC3.16MShares$20.7 Million0.0% of portfolio
-
Ubs Group Ag2.87MShares$18.8 Million0.0% of portfolio
-
Jackson Square Partners, LLC San Francisco, CA1.61MShares$10.6 Million0.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.56MShares$10.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.43MShares$9.4 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY974KShares$6.39 Million0.0% of portfolio
-
Apollo Management Holdings, L.P. New York, NY672KShares$4.41 Million0.05% of portfolio
-
Geode Capital Management, LLC Boston, MA581KShares$3.81 Million0.0% of portfolio
-
State Street Corp Boston, MA445KShares$2.92 Million0.0% of portfolio
Latest Institutional Activity in SGHT
Top Purchases
Top Sells
About SGHT
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Insider Transactions at SGHT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 17
2024
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
13,066
-3.07%
|
$65,330
$5.42 P/Share
|
|
Apr 03
2024
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
3,128
-0.18%
|
$15,640
$5.08 P/Share
|
|
Apr 03
2024
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
12,571
-0.22%
|
$62,855
$5.08 P/Share
|
|
Apr 03
2024
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,893
-2.82%
|
$24,465
$5.08 P/Share
|
|
Apr 03
2024
|
Sam Boong Park Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,414
-1.29%
|
$17,070
$5.08 P/Share
|
|
Apr 03
2024
|
Alison Bauerlein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,123
-2.32%
|
$50,615
$5.08 P/Share
|
|
Feb 14
2024
|
David Badawi Chief Technology Officer |
SELL
Grant, award, or other acquisition
|
Direct |
108,645
-5.8%
|
-
|
|
Feb 14
2024
|
Alison Bauerlein Chief Financial Officer |
SELL
Grant, award, or other acquisition
|
Direct |
315,421
-41.96%
|
-
|
|
Feb 14
2024
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Grant, award, or other acquisition
|
Direct |
151,869
-46.67%
|
-
|
|
Feb 14
2024
|
Paul Badawi President and CEO |
SELL
Grant, award, or other acquisition
|
Direct |
390,187
-6.34%
|
-
|
|
Feb 14
2024
|
Sam Boong Park Chief Operating Officer |
SELL
Grant, award, or other acquisition
|
Direct |
151,869
-36.42%
|
-
|
|
Jan 17
2024
|
Paul Badawi President and CEO |
SELL
Open market or private sale
|
Direct |
15,917
-0.3%
|
$79,585
$5.16 P/Share
|
|
Jan 17
2024
|
David Badawi Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
3,414
-0.21%
|
$17,070
$5.16 P/Share
|
|
Jan 17
2024
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,538
-30.55%
|
$22,690
$5.16 P/Share
|
|
Jan 17
2024
|
Sam Boong Park Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,443
-5.13%
|
$27,215
$5.16 P/Share
|
|
Jan 03
2024
|
Jeremy B. Hayden Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,227
-7.63%
|
$6,135
$5.17 P/Share
|
|
Jan 03
2024
|
Paul Badawi President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,975
-0.17%
|
$44,875
$5.17 P/Share
|
|
Jan 03
2024
|
David Badawi Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,425
-0.15%
|
$12,125
$5.17 P/Share
|
|
Jan 03
2024
|
Sam Boong Park Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,464
-2.27%
|
$12,320
$5.17 P/Share
|
|
Dec 27
2023
|
D1 Capital Partners L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,852,036
-48.74%
|
$14,260,180
$5.86 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 901K shares |
|---|---|
| Open market or private purchase | 985K shares |
| Exercise of conversion of derivative security | 188K shares |
| Open market or private sale | 2.93M shares |
|---|---|
| Grant, award, or other acquisition | 1.12M shares |
| Payment of exercise price or tax liability | 15.1K shares |